Stable oxaliplatin-encapsulating liposome aqueous dispersion and method for stabilizing same
View Patent ↗An object of the present invention is to provide an oxaliplatin-encapsulating liposome aqueous dispersion that has excellent long-term storage stability. The present invention provides an aqueous dispersion of liposomes encapsulating oxaliplatin, the oxaliplatin-encapsulating liposome aqueous dispersion containing 2-morpholinoethanesulfonic acid in an external aqueous phase.
1. A method for stabilizing an oxaliplatin-encapsulating liposome aqueous dispersion, comprising adding 2-morpholinoethanesulfonic acid or a salt thereof to the oxaliplatin-encapsulating liposome aqueous dispersion in an amount sufficient to stabilize said oxaliplatin-encapsulating liposome aqueous dispersion, wherein the liposome comprises, as a liposome component, hydrogenated purified soybean phosphatidylcholine, wherein the oxaliplatin-encapsulating liposome aqueous dispersion has a pH of 6 to 8, wherein the dispersion comprises an internal aqueous phase that substantially contains no 2-morpholinoethanesulfonic acid.
2. The method according to claim 1 , wherein the 2-morpholinoethanesulfonic acid has a concentration of 0.1 to 5 mM.
3. The method according to claim 1 , wherein the oxaliplatin-encapsulating liposome aqueous dispersion has a pH of 6 to 7.
4. The method according to claim 1 , wherein said 2-morpholinoethanesulfonic acid or a salt thereof is added to the oxaliplatin-encapsulating liposome aqueous dispersion after formation of the oxaliplatin-encapsulating liposome.
5. The method according to claim 1 , wherein the 2-morpholinoethanesulfonic acid or a salt thereof is added in the form of a solution or powder to the external aqueous phase.
6. A method for stabilizing an oxaliplatin-encapsulating liposome aqueous dispersion, comprising forming an oxaliplatin-encapsulating liposome aqueous dispersion with an internal aqueous phase and an external aqueous phase, and then replacing the external aqueous phase with a buffer containing 2-morpholinoethanesulfonic acid or a salt thereof in an amount sufficient to stabilize said oxaliplatin-encapsulating liposome aqueous dispersion, wherein the liposome comprises, as a liposome component, hydrogenated purified soybean phosphatidylcholine, wherein the external aqueous phase of the oxaliplatin-encapsulating liposome aqueous dispersion has a pH of 6 to 8, and wherein the internal aqueous phase contains substantially no 2-morpholinoethanesulfonic acid.
7. The method according to claim 1 , wherein said 2-morpholinoethanesulfonic acid or a salt thereof is added in an amount sufficient to prevent the formation of precipitates or aggregates after storage at 2-8° C. for six months.
8. A method for stabilizing an oxaliplatin-encapsulating liposome aqueous dispersion, comprising:
a) preparing a lipid solution,
b) preparing an oxaliplatin solution,
c) adding the lipid solution to the oxaliplatin solution to produce an oxaliplatin-encapsulating liposome aqueous dispersion,
d) adding 2-morpholinoethanesulfonic acid or a salt thereof to the oxaliplatin-encapsulating liposome aqueous dispersion in an amount sufficient to stabilize said oxaliplatin-encapsulating liposome aqueous dispersion,
wherein the liposome comprises, as a liposome component, hydrogenated purified soybean phosphatidylcholine, wherein the oxaliplatin-encapsulating liposome aqueous dispersion has a pH of 6 to 8, and wherein the dispersion comprises an internal aqueous phase that substantially contains no 2-morpholinoethanesulfonic acid.